To remain relevant in an interconnected ecosystem, biopharma must go beyond optimising yesterday’s markets and begin ...

NICE is also looking at the role of Hympavzi in treating severe haemophilia A, where there are other subcutaneous options ...

According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and, in most cases, resolve within a ...

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...

The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

After losing ground in commercial clinical trials in recent years, the UK has now turned a corner and is once again taking a ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Sexual health services in the UK will start rolling out a 'world-first' vaccine programme designed to protect people from ...

Arguably, the step historically limiting growth of the radiotherapeutics sector is radioisotope generation. Isotopes are ...